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Abstract 47 
Transmissible spongiform encephalopathies (prion diseases) in animals may be associated 48 
with a zoonotic risk potential for humans as shown by the occurrence of variant Creutzfeldt-49 
Jakob disease in the wake of the bovine spongiform encephalopathy epidemic. Thus, the 50 
increasing exposure of humans in North America to cervid prions of chronic wasting disease 51 
(CWD) in elk and deer has prompted comprehensive risk assessments. The susceptibility of 52 
humans to CWD infections is currently under investigation in different studies using 53 
macaques as primate models. The necessity for such studies was recently reinforced when 54 
disease-associated prion protein and its seeding activity were detected in muscles of 55 
clinically inconspicuous CWD-infected white-tailed deer. Increasing evidence points to the 56 
existence of different CWD strains, and CWD prions may also change or newly emerge over 57 
time. Therefore, CWD isolates examined in macaques should be characterized as precisely 58 
as possible for their molecular identity. On this basis other CWD field samples collected in 59 
the past, present or future could be systematically compared to macaque-tested inocula in 60 
order to assess whether they are covered by the ongoing risk assessments in primates. 61 
CWD typing by Fourier transform-infrared spectroscopy of pathological prion protein may 62 
provide a method of choice for this purpose.     63 
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Transmissible spongiform encephalopathies: Prion diseases with a zoonotic risk 64 
potential   65 
Transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative diseases 66 
caused by prions (proteinaceous infectious particles) such as chronic wasting disease 67 
(CWD) in cervids, scrapie in sheep, bovine spongiform encephalopathy (BSE), or human 68 
Creutzfeldt-Jakob disease (CJD).1 While some TSEs have been known since long (e. g. 69 
scrapie or CJD) others emerged only in recent years. Of the latter, particularly BSE and 70 
variant Creutzfeldt-Jakob disease (vCJD) attracted great attention in science, politics and the 71 
media. The occurrence of vCJD in the wake of the BSE epidemic showed that animal prions 72 
may potentially breach the species barrier to humans via the alimentary route.2 This hazard 73 
has called for a stringent surveillance and control of prion reservoirs in farmed livestock and 74 
hunted game.   75 
CWD and other prions are thought to consist essentially of host-encoded prion protein (PrP) 76 
with a pathological, β-sheet rich folding- and aggregation structure, referred to as PrPSc or 77 
PrPTSE.1,3,4 Their replication is putatively mediated by a process of seeded polymerization in 78 
which seeding-active nuclei of PrPTSE recruit cellular prion protein (PrPC) and incorporate it, in 79 
a misfolded form, into growing amyloid-like PrP aggregates. When such polymers break up 80 
into smaller units this leads to a multiplication of PrP particles with proteinaceous seeding 81 
activity further mediating the autocatalytic replication of the pathological protein state. Prion-82 
associated seeding activity converting normal protease-sensitive PrPC into Proteinase K-83 
resistant prion protein (PrPres) can be monitored in vitro by protein misfolding cyclic 84 
amplification (PMCA).5 85 
 86 
Exposure of humans to CWD prions  87 
Chronic wasting disease is a TSE in white-tailed deer, mule deer, Rocky Mountain elk and 88 
moose. Over the past years this disease has shown a sustained spread in captive as well as 89 
free-ranging cervids in North America.6,7 The increasingly frequent and widespread 90 
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occurrence of affected animals is likely to augment the exposure of humans to the CWD 91 
agent. Prion infectivity or TSE-associated prion protein have been detected in the central and 92 
peripheral nervous system, in a variety of lymphoid tissues as well as in heart muscle, blood, 93 
saliva, feces and urine of CWD-infected cervids7. Also, infectious CWD agent was found in 94 
antler velvet of elk and in skeletal muscles of mule deer with chronic wasting disease.8,9 95 
Thus, particularly persons processing cervid carcasses, users of medicinal products made 96 
from antler velvet and consumers of venison may be exposed to an elevated risk for 97 
contamination with CWD prions.  98 
Recently, PrPTSE and its proteinaceous seeding activity could be directly demonstrated, for 99 
the first time, in skeletal muscles of CWD-infected cervids.10 The animals examined in this 100 
study were farmed and free-ranging WTD for which no clinical signs of CWD had been 101 
recognized. However, they had been officially confirmed positive for CWD based on the 102 
detection of PrPTSE in brain tissue or lymph nodes and were thus apparently in a state of pre- 103 
or subclinical infection. Muscles from such clinically inconspicuous carrier animals appear 104 
more likely to enter the human food chain than meat from cervids that show symptoms of 105 
CWD. Whether this may provide a relevant mode for the inadvertent foodborne transmission 106 
of CWD prions is still unclear. Yet, the presence and seeding activity of PrPTSE in skeletal 107 
muscles of pre- or subclinically infected WTD reinforced the need to comprehensively assess 108 
whether humans are susceptible to zoonotic CWD infections.  109 
 110 
CWD risk assessments 111 
Transmissibility to other animal species 112 
CWD has been observed under natural conditions so far only in cervids. However, the 113 
disease could be transmitted experimentally to recipients such as vole species, golden 114 
hamsters, minks, ferrets, goats and cattle.7 Thus, in artificial setups CWD prions were able to 115 
breach the species barrier to different kinds of wild and domestic animals. It remains 116 
unknown, though, whether inter-species transmission of CWD would be also possible via 117 
 6 
natural routes of exposure such as contact to infected cervids or environments contaminated 118 
with CWD.  119 
 120 
Transmissibility to humans  121 
The current state of epidemiological research suggests a rather robust barrier for the 122 
transmission of CWD to humans. Particularly, the surveillance of human prion diseases in 123 
areas with a long history of endemic CWD such as Colorado and Wyoming did not reveal 124 
evidence for zoonotic transmissions of the disease to cervid hunters or consumers of meat 125 
from elk and deer.6,11 However, as discussed by Belay et al.,6 the intensity of human 126 
exposure to CWD prions may increase due to a further spread and rising prevalence of the 127 
disease in cervids. Therefore, and with the generally long latency periods of human prion 128 
diseases in mind, previous epidemiological findings cannot be readily extrapolated.  129 
Until recently, experimental studies that pursued biochemical approaches or used transgenic 130 
mice to ascertain the susceptibility of humans to CWD infections consistently seemed to 131 
corroborate current epidemiological findings: CWD-infected cervid brain tissue did not seed 132 
the conversion of PrPC into PrPres in PMCA assays using brain homogenate from macaques 133 
or transgenic mice expressing human PrPC as test substrate12, and transgenic mice 134 
overexpressing human PrPC were resistant to infection after intracerebral challenge with 135 
CWD prions from mule deer.13 However, a study published by Barria et al.14 in March 2011 136 
found that cervid PrPTSE can seed the conversion of human PrPC into PrPres by PMCA when 137 
the CWD agent has been previously passaged in vitro or in vivo. Specifically, this was 138 
demonstrated for CWD prions from naturally affected mule deer either passaged by serial 139 
PMCA using deer PrPC as conversion substrate or in transgenic mice expressing cervid 140 
PrPC. The authors of this study pointed out that CWD prions may undergo a gradual process 141 
of change and adaptation via successive passages in the cervid population. They concluded 142 
that the reported findings, if corroborated by infectivity assays, may imply “that CWD prions 143 
have the potential to infect humans and that this ability progressively increases with CWD 144 
spreading”.  145 
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Cynomolgus macaques used as a primate model for testing the susceptibility of humans to 146 
CWD as close to reality as possible have not shown clinical signs of a prion disease at nearly 147 
6 years after intracerebral or peroral inoculation of CWD agents from white-tailed deer, 148 
Rocky Mountain elk or mule deer.15 In contrast to macaques squirrel monkeys were 149 
susceptible to CWD infection by the intracerebral route and showed even a low rate of 150 
disease transmission after oral challenge.15,16 Since humans are phylogenetically closer 151 
related to macaques than to squirrel monkeys, macaques are regarded as the more relevant 152 
primate model for assessing the zoonotic transmissibility of CWD.15 153 
 154 
Ongoing transmission studies in macaques 155 
Additionally to the primate study by Race et al.15 two further studies in which macaques were 156 
challenged with tissue homogenates from CWD-affected cervids by intracerebral inoculation 157 
or via the oral route have been reported to be in progress.17,18 The purpose, research effort, 158 
financial investment and ethical aspects of these studies demand an utmost experimental 159 
scrutiny, careful data analysis and thorough exploitation of results. This has two immediate 160 
implications:  161 
i)    Since the incubation period of CWD may be very long in case of primary  162 
(i. e. inter-species) transmission to macaques a sustained monitoring of the 163 
animals appears mandatory for many years despite negative interim 164 
findings.  165 
ii)    Increasing evidence suggests the existence of different CWD agents (see 166 
below), and theoretically CWD prions may also change over time thereby 167 
possibly altering their potential host range. Thus, CWD isolates used in 168 
individual or pooled inocula for the challenge of macaques should be typed 169 
as precisely as possible in terms of their strain characteristics and molecular 170 
identity. Other field isolates could then be checked for their similarity or 171 
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dissimilarity to the macaque-tested CWD agents in order to ascertain 172 
whether or not they are covered by the ongoing primate risk assessments.    173 
 174 
Evidence for distinct CWD strains 175 
Biochemical indications for isolate-dependent structural differences of PrPTSE     176 
In 2002 it was reported that glycoform patterns of PrPTSE showed differences among 177 
individual CWD-affected cervids.19 In a variety of studies the glycosylation of PrPTSE had 178 
been previously established as a biochemical feature that may differ between distinct TSE 179 
agents.20,21 Accordingly, the finding by Race et al. possibly indicated CWD infections with 180 
different or multiple strains of agent, although alternatively it could be explained also by 181 
random selection from a heterogeneous population of CWD-affected ruminants.19 182 
Using a conformation-dependent immunoassay (CDI) Safar et al. found evidence for different 183 
conformations of PrPTSE in elk CWD as compared to white-tailed and mule deer CWD.22 184 
However, the amino acid sequences of elk and deer PrPC differ at residues 226 (glutamic 185 
acid in elk and glutamine in deer), and it remained to be established whether the structural 186 
differences detected by CDI were related to biologically distinct CWD strains.    187 
 188 
Isolation of CWD-associated agents causing distinct phenotypes in laboratory rodents    189 
Classically, prion strains are differentiated based on their incubation periods in inbred mice 190 
with distinct PrP genotypes and by lesion profiles of the vacuolation in selected brain areas 191 
of reporter animals.23 When Raymond et al. serially passaged a CWD inoculum from mule 192 
deer either in Syrian hamsters, or first into transgenic mice expressing hamster PrPC, and 193 
then further on in hamsters, they obtained two distinct isolates termed SghaCWDmd-f and 194 
SghaCWDmd-s, respectively.24 The first isolate showed an about fivefold shorter incubation 195 
period in Syrian hamsters than the latter, and the cerebral patterns of PrPTSE deposition and 196 
gliosis in clinically affected hamsters were also different. Based on their findings the authors 197 
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concluded that the “cervid-derived inocula may have contained or diverged into at least two 198 
distinct transmissible spongiform encephalopathy strains”.  199 
Angers et al. transmitted CWD inocula from elk and deer to transgenic mice expressing 200 
cervid PrP and found that these mice were affected by one of two strains, referred to as 201 
CWD1 and CWD2, that caused different incubation times and lesion profiles.25 The results of 202 
this study “appear to reflect strain constitutions in the natural host, rather than adaptation and 203 
divergence of progenitor strains in recipient mice…” according to the authors. Interestingly, 204 
CWD1 and CWD2 did not show recognizably different biochemical properties of their PrPTSE. 205 
The electrophoretic migration and glycosylation patterns as well as the stability 206 
characteristics after treatment with guanidine hydrochloride were indistinguishable for 207 
CWD1- and CWD2-associated PrPTSE. Consistent with these findings it has been previously 208 
reported that biologically distinct prion strains cannot always be differentiated by biochemical 209 
PrPTSE-typing or characterization of the conformational stability of PrPTSE.26,27 210 
 211 
Rationale for the typing of CWD agents by Fourier transform-infrared (FT-IR) 212 
spectroscopy 213 
The precise identification of present and newly emerging CWD strains in the field is of great 214 
importance for a reliable risk assessment. When it comes to the typing of CWD agents that 215 
have been used to challenge macaques and of other CWD field isolates for comparative 216 
purposes, a comprehensive biological characterization in rodent models would be laborious, 217 
time-consuming and in practical respect possibly even unfeasible. On the other hand, 218 
biochemical surrogate methods for prion typing may fail to sufficiently discriminate between 219 
different PrPTSE species associated with distinct CWD agents. The biophysical discrimination 220 
of CWD isolates by infrared spectroscopy of pathological prion protein may provide a resort 221 





Infrared spectroscopy delivers information about structural characteristics of proteins  226 
The glycosylation and/or the folding and aggregation structure of PrPTSE mirror phenotypic 227 
characteristics of prion strains and have been also suggested as molecular codes that 228 
encipher strain-specific information of TSE agents.20,21,26,28–30 Infrared spectroscopy has been 229 
established as a powerful tool for studying structural properties of proteins. Secondary 230 
structure motifs of proteins are reflected in IR spectral absorption bands, and the frequency 231 
positions of structure-sensitive amide band components can be assigned to specific types of 232 
secondary structure such as -helix, β-sheet, or turn.31 The amide I band of IR spectra 233 
extends from about 1600 to 1700 wavenumbers per cm and primarily represents the 234 
carbonyl stretching vibration of the peptide backbone. This band is influenced by a variety of 235 
factors such as the strength of hydrogen bonds and the packing of β-strands.32,33 236 
 237 
Discrimination of prion strains by infrared spectroscopy of PrPTSE  238 
The amide I band of IR spectra was shown in previous studies to mirror structural differences 239 
in intra- und intermolecular β-sheets, -helices and turns of PrPTSE from different prions 240 
strains. Using  Fourier transform-infrared (FT-IR) spectroscopy Caughey et al. had been able 241 
to demonstrate that PrPTSE extracts from the brains of hamsters infected with hyper- and 242 
drowsy strains of transmissible mink encephalopathy showed different β-sheet structures.30 243 
In a later study, Thomzig et al. examined PrPTSE from three different hamster-adapted 244 
scrapie strains (263K, ME7-H, 22A-H) and a hamster-adapted BSE isolate (BSE-H) by FT-IR 245 
spectroscopy.26 Two of these agents, ME7-H and 22A-H, differed only with respect to their 246 
incubation times in hamsters. Apart from that they caused indistinguishable clinical 247 
symptoms and neuropathological lesion profiles. Differences between the electrophoretic 248 
mobilities or glycosylation patterns of their PrPTSE could not be detected. Paraffin-embedded 249 
tissue (PET) blotting of the cerebral PrPTSE distribution and Western blotting for testing the 250 
conformational stability of PrPTSE after exposure to Proteinase K at different pH values also 251 
failed to display discrepancies between the ME7-H and 22A-H scrapie strains. However, all 252 
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four TSE agents examined in the study by Thomzig et al., including ME7-H and 22A-H, could 253 
be clearly distinguished from each other by distinct structural features of their particular 254 
PrPTSE represented in the amide I absorption patterns of FT-IR spectra.  255 
The consistency and discriminatory significance of the spectral profiles reported by Thomzig 256 
et al. could be objectively confirmed by multivariate statistics. In a hierarchical cluster 257 
analysis the distinct amide I absorption features reliably produced four clusters of spectra, 258 
each correctly including the spectra from PrPTSE associated with one of the four different 259 
isolates.34 Thus, FT-IR spectroscopy was shown to provide a “fingerprint” of β-sheet- and 260 
other secondary structure components in PrPTSE that may be used for the swift typing of prion 261 
strains without restrictions to specific TSEs or host species.  262 
 263 
Outlook   264 
Figure 1 provides an outline of how CWD agents could be perspectively typed by FT-IR 265 
spectroscopy. If CWD isolates contained only single prion strains their classification would 266 
appear theoretically feasible simply by straightforward FT-IR spectroscopical characterization 267 
of PrPTSE purified from affected cervids. However, if mixtures of different strains were present 268 
in test samples such direct FT-IR spectroscopy of PrPTSE from affected cervids may not allow 269 
a proper typing. In principle, this potential drawback could be dispelled by the separation and 270 
cloning of agents prior to further analyses. Usually, this would have required comprehensive 271 
passages of isolates in animals.23 However, due to substantial technical advancements the 272 
PMCA technology now provides an in vitro option for the selective amplification of PrPres 273 
from distinct CWD strains.5,35,36 For this purpose PMCA would need to be performed 274 
repeatedly with limiting dilutions of CWD seeding activity. Amplificates of PrPres derived from 275 
CWD agents by this approach could be subjected additionally or alternatively to PrPTSE from 276 
cervids to subsequent FT-IR analyses for a tentative structure-based classification of CWD 277 
agents.  278 
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We have recently found that highly-resolved FT-IR spectra for strain differentiation can be 279 
conveniently obtained from purified preparations of PMCA-derived scrapie-associated PrPres 280 
(manuscript in preparation). However, whether PrPTSE isolated from CWD-affected cervids or 281 
PrPres amplified by PMCA will eventually provide practical analytes for the typing of CWD 282 
prions by FT-IR spectroscopy requires further research. More clarity about the similarities or 283 
dissimilarities between the CWD inocula that have been administered to macaques and the 284 
variety of field isolates which cannot be tested in this way would be worth the effort. 285 
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Figure legends 401 
Figure 1 402 
Typing of CWD agents by FT-IR spectroscopy of strain-related misfolded prion protein  403 
Unknown CWD field isolates may contain single or multiple strains of agent. For the typing of 404 
CWD agents by FT-IR spectroscopy purified PrPTSE from cervids affected with a single strain 405 
only could be directly examined. However, mixtures of distinct CWD agents would need to be 406 
separated into single strains prior to FT-IR spectroscopic analysis. Perspectively, this may be 407 
achieved by PMCA repeatedly performed with limiting dilutions of CWD seeding activity  408 
(limiting dilutions would be identified as the highest dilutions of CWD test samples that still 409 
show a detectable seeding activity, i. e. formation of PrPres). If a test sample contained two 410 
CWD strains, A and B, and the seeding activity of strain A exceeded that of strain B under 411 
specific PMCA conditions, PMCA performed with limiting dilutions should selectively amplify 412 
PrPres derived from strain A. Vice versa, PrPres derived from strain B should be selectively 413 
amplified if the seeding activity of this strain exceeded that of strain A. Thus, amplification of 414 
PrPres from the CWD strain with the relatively highest seeding activity should be achieved by 415 
the depicted analytical approach. It has to be noted that the relative seeding activities of 416 
different strains in a given CWD isolate i) do not need to quantitatively correlate with the 417 
relative amounts of their respective PrPTSE and ii) may depend on the specific PMCA 418 
conditions used for PrPres amplification. Therefore, if aliquots of a CWD isolate were 419 
processed under differing PMCA conditions favouring the amplification of PrPres from 420 
different strains, this could potentially allow the isolation of PrPres amplificates from two or 421 
more CWD strains in the sample.  422 
Once highly purified PrPTSE extracts or PrPres amplificates have been prepared, these can 423 
be subjected to FT-IR spectroscopy. The obtained spectral information comprised in the 424 
amide I absorption band between about 1600 to 1700 wavenumbers/cm should provide a 425 
structural fingerprint of β-sheets (low frequency, a), unassigned structure (b), -helices (c), 426 
turns (d) and turns/β-sheets (high frequency, e) of the examined PrPTSE/PrPres as shown in 427 
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the FT-IR second derivative spectrum of the figure. This spectral information can be used as 428 
input data for a hierarchical cluster analysis in order to obtain an objective sample 429 
classification in terms of tentative CWD strain assignments.26,34 Abbreviations: A, CWD strain 430 
A; B, CWD strain B. Symbols: Circles, misfolded prion protein associated with or PMCA-431 
derived from CWD strain A; Triangles, misfolded prion protein associated with or PMCA-432 
derived from CWD strain B.  433 
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